Topics:

Pneumococcal Pneumonia:

Pneumococcal Pneumonia:

Sir William Osler once called pneumococcal pneumonia "the captain of the men of death."1 Pneumoniais the sixth leading cause of death in the United States and the fourth leading cause among Americans 80 years of age and older.2

Mortality has not decreased appreciably since the 1950s. Among patients with community-acquired pneumonia, mortality approaches 20% in those with bacteremia and 37% in those admitted to the ICU.3 Advanced age and comorbid illnesses-such as congestive heart failure, chronic obstructive pulmonary disease, neoplastic disease, and diabetes mellitus-are also associated with increased mortality.

Here we provide our recommendations for diagnosing, managing, and preventing pneumococcal pneumonia. We focus on clues in the workup, the impact of penicillin resistance on empiric therapy, and vaccination and other effective preventive measures.

INCIDENCE

Fang and colleagues4 evaluated 359 consecutive admissions for community-acquired pneumonia and found that the most common causative organism was Streptococcus pneumoniae (15.3% of admissions). The cause was undetermined in 32.9%.

Conventional methods-including sputum and blood culture and serology-typically identify the causative organism in only 50% of patients with community-acquired pneumonia. In one study, transthoracic needle aspiration was used in patients in whom conventional diagnostic methods had failed. S pneumoniae was found to be the most common pathogen; it was detected in one third of the cases in the study.5 Overall, pneumococcal infection accounts for an estimated 36% of all cases of community-acquired pneumonia.6

DIAGNOSIS

Clinical clues to the diagnosis of pneumococcal pneumonia include a history of fever, shaking chills, pleuritic chest pain, and a cough productive of rust-colored sputum. Elderly patients often have fewer or less severe symptoms than younger patients.

Laboratory studies usually reveal leukocytosis. Radiographic findings often suggest the causative agent.7 The most common infiltrates caused by pneumonia are lobar, lobular, and interstitial; S pneumoniae infection is most often associated with a lobar infiltrate (Box).

A study of 24 patients with radiographically proven lobar pneumonia found that the auscultatory findings with the highest sensitivity were rales, bronchial breath sounds, and egophony.8 Egophony-which can be defined as a change in the pronunciation of a sound-is a common finding in lobar pneumonia. To detect egophony, ask the patient to say "E" and auscultate for its transformation to "A".9

COMPLICATIONS

Bacteremia. This complication occurs in approximately 25% to 30% of patients with pneumococcal pneumonia.6 In adults, the incidence of invasive pneumococcal disease increases with age (Figure 1). Mortality rates for patients with bacteremic pneumococcal disease range from 20% to 30% but can be as high as 60% in elderly patients.

Parapneumonic effusion. Pleural effusions develop in 40% of hospitalized patients with pneumococcal pneumonia; however, fewer than 5% of cases progress to empyema.10 If more than a minimal amount of fluid is present-as evidenced by significant blunting of the costophrenic angle-order Gram staining and culture of the fluid obtained by thoracentesis; the fluid should also be analyzed for glucose and lactate dehydrogenase (LDH) levels, pH, and differential cell count.11 Low pleural fluid pH, a low glucose level, a high LDH level, and a positive Gram stain result characterize complicated parapneumonic effusions. A differential cell count that consists predominantly of polymorphonuclear leukocytes is common in patients with parapneumonic effusion. Chest tube drainage is indicated if any of the following are present:

Frank pus.

Pleural fluid glucose level of less than 40 mg/dL.

Fluid pH of less than 7.0.

Fluid pH of less than 7.2 and LDH level of greater than 1000 U/L.12

If the pleural fluid glucose level is greater than 60 mg/dL, the pH is greater than 7.2, the LDH level is less than 1000 U/L, and the pleural fluid cultures are negative, the patient can be given antimicrobial therapy and observed.

TREATMENT

Penicillin resistance. In the 1940s, widespread use of penicillin helped reduce mortality from S pneumoniae infections. Pneumococcal resistance to penicillin was first reported in the 1960s. However, resistance was not considered a major problem in the United States until the early 1990s. The prevalence of antibiotic- resistant S pneumoniae has increased over the past 10 years. One study showed that 25% of isolates from patients with bacteremia were not susceptible to penicillin.13

S pneumoniae is considered penicillin-sensitive if the minimal inhibitory concentration (MIC) is 0.06 µg/mL or less, intermediately susceptible if the MIC is between 0.1 µg/mL and 1 µg/mL, and resistant if the MIC is 2 µg/mL or higher.14 The Drug-Resistant Streptococcus pneumoniae (DRSP) Therapeutic Working Group has established the following cutoff points for the susceptibility of S pneumoniae to penicillin:

Susceptible if the MIC is 1 µg/mL or less.

Intermediately susceptible if the MIC is 2 µg/mL.

Resistant if the MIC is 4 µg/mL or higher.15

We prefer to use the DRSP Ther-apeutic Working Group's cutoff points.

Empiric therapy. The emergence of drug-resistant pneumococci and the development of new antimicrobials have changed the empiric treatment of community-acquired pneumonia. Newer fluoroquinolones with activity against S pneumoniae offer alternatives in the treatment of drug-resistant S pneumoniae infection.16 More recently available macrolides, such as azithromycin and clarithromycin, may be preferable to erythromycin because of better GI tolerance.

For outpatients with community-acquired pneumonia, the DRSP Therapeutic Working Group recommends an oral macrolide (eg, erythromycin, clarithromycin, or azithromycin) or an oral β-lactam (eg, cefuroxime, amoxicillin, or amoxicillin-clavulanate). An oral fluoroquinolone with activity against S pneumoniae can be substituted if the patient is allergic to macrolides or β-lactams.

For hospitalized patients with community-acquired pneumonia, an intravenous β-lactam (eg, cefuroxime, cefotaxime, ceftriaxone, or ampicillin-sulbactam) and an intravenous macrolide (eg, erythromycin, clarithromycin, or azithromycin) are recommended. A fluoroquinolone with activity against S pneumoniae can be substituted. For critically ill hospitalized patients, an intravenous third-generation cephalosporin, such as cefotaxime or ceftriaxone, and an intravenous macrolide should be used. Again, a fluoroquinolone with activity against S pneumoniae can be substituted.15

The DRSP Therapeutic Working Group does not recommend the newer fluoroquinolones as first-line treatment because of concerns that resistance among pneumococci will rapidly emerge with widespread use of these antimicrobials. Reserve fluoroquinolones for patients who are allergic to alternative agents, who have failed to respond to a first-line agent, or who have a documented infection with highly drug-resistant pneumococci (ie, penicillin MIC of 4 µg/mL or higher).

PREVENTION

Pneumococcal vaccine. The first pneumococcal vaccine was licensed in the United States in 1977. This 14-valent vaccine was replaced by the current 23-valent vaccine in 1983. There are over 80 serotypes of pneumococci that cause pneumonia, but the 23 serotypes covered by the pneumococcal vaccine are responsible for 88% of bacteremic isolates.17

Vaccination is recommended for all persons aged 65 years and older, all adults with chronic cardiopulmonary diseases, and all immunocompromised persons (Algorithm).18Although only about 14% of adults aged 65 years and older received the pneumococcal vaccine in 1993,17 this percentage increased to 35.6% in 1995.19 A more recent study showed that among high-risk patients (ie, persons aged 65 years or older with chronic cardiopulmonary diseases), only 26% were currently immunized against pneumococcal infection.20

The vaccine is approximately 50% to 80% effective in preventing bacteremic pneumococcal disease.21 However, this effectiveness decreases with time. Figure 2 shows calculated age-specific estimates of the effectiveness of pneumococcal vaccination in preventing bacteremia.22

Consider revaccination every 6 years in patients known to have a rapid decline in antibody titers, such as those with nephrotic syndrome or renal failure. Also consider repeating pneumococcal vaccination in asplenic patients. Revaccination has minimal side effects; the most common is a localized reaction at the site of injection.23

Influenza vaccine. The association between influenza virus infection and pneumonia is well recognized.24,25 The number of cases of invasive pneumococcal disease peaks in midwinter, when influenza is prevalent. Influenza virus infection can facilitate bacterial colonization and impair host defense mechanisms.

Vaccination against influenza is helpful in preventing secondary pneumonia and reducing the need for hospitalization. The vaccine is approximately 30% to 40% effective in preventing clinical illness. However, like the pneumococcal vaccine, it is highly underused in the elderly.17 One study showed that among high-risk patients, only 34% were currently immunized against influenza.20

Additive benefits of immunization. A study of elderly patients with chronic lung disease found additive benefits of the influenza and pneumococcal vaccines in reducing hospitalizations for pneumonia. During the influenza season, influenza vaccination alone was associated with a 52% reduction in hospitalizations for pneumonia. Pneumococcal vaccination alone was associated with a 27% reduction in hospitalizations for pneumonia. When both vaccines had been given, the reduction in hospitalizations for pneumonia was 63%.26

A prospective study of patients 65 years of age and older demonstrated the effectiveness of influenza and pneumococcal vaccination both in the reduction of hospitalizations for pneumonia and in the prevention of invasive pneumococcal disease. Among vaccinated patients, hospitalizations for pneumococcal pneumonia were reduced by 36% and the incidence of invasive pneumococcal disease was reduced by 52%.27

References

REFERENCES:
1. Feikin, DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1996-1997. Am J Public Health. 2000;90:223-229.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
3. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 1996;275:134-141.
4. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore). 1990;69:307-316.
5. Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med. 1999;106:385-389.
6. Epidemiology and Prevention of Vaccine-Preventable Diseases. 7th edition. Available at: http://www.cdc. gov/nip/publications/pink/pneumo.pdf.
7. Montgomery JL. Pneumonia. Pearls for interpreting patients' radiographs. Postgrad Med. 1991; 90:58-66, 69-73.
8. Wipf JE, Lipsky BA, Hirschmann JV. Diagnosingpneumonia by physical examination: relevant or relic? Arch Intern Med. 1999;159:1082-1087.
9. Sapira JD. About egophony. Chest. 1995;108: 865-867.
10. Heffner JE. Indications for draining a parapneumonic effusion: an evidence-based approach. Semin Respir Infect. 1999;14:48-58.
11. Light RW, Rodriguez RM. Management of parapneumonic effusions. Clin Chest Med. 1998;19:373-382.
12. Light RW. Parapneumonic effusions and empyema. Clin Chest Med. 1985;6:55-62.
13. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995;333:481-486.
14. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. 5th ed. NCCLS document M7-A5. Wayne, Pa: NCCLS; January 2000.
15. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a Report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160: 1399-1408.
16. Moss PJ, Finch RG. The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults. Thorax. 2000;55:83-85.
17. Gardner P, Schaffner W. Immunization of adults. N Engl J Med. 1993;328:1252-1258.
18. Prevention of Pneumococcal Disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1997;46:1-24.
19. Pneumococcal and influenza vaccination lev- els among adults aged greater than or equal to 65 years--United States, 1995. MMWR. 1997;46: 913-919.
20. Chan-Tack KM. Influenza and pneumococcal immunization rates among a high-risk population. South Med J. 2001;94:323-324.
21. Fedson DS. The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine. 1999; 17(suppl 1):S85-S90.
22. Sisk JE, Moskowitz AJ, Whang W, et al. Cost- effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA. 1997;278: 1333-1339.
23. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 1999;281:243-248.
24. Kim PE, Musher DM, Glezen WP, et al. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis. 1996;22: 100-106.
25. Cate TR. Impact of influenza and other community-acquired viruses. Semin Respir Infect. 1998; 13:17-23.
26. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine. 1997;17(suppl 1):S91-S93.
27. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet. 2001;357:1008-1011.

 
Loading comments...
Please Wait 20 seconds or click here to close